Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Linear IgA Disease

Dermatologic

Linear IgA Disease (LADB) Clinical Trials and Treatments

Also called LADB, autoimmune blistering, linear IgA bullous dermatosis

Linear IgA disease (LADB) is an autoimmune blistering disorder characterized by linear IgA deposits at the basement membrane zone on direct immunofluorescence, distinguishing it from other bullous autoimmune conditions. The condition may be drug-induced (particularly from vancomycin, NSAIDs, beta-blockers, or other medications) or idiopathic in etiology. Pathophysiologically, circulating IgA autoantibodies recognize basement membrane antigens including BP180, BP230, or other components, forming immune complexes that deposit along the dermal-epidermal junction.

In plain words, linear IgA disease is a rare condition where the immune system attacks the skin using an immune protein called IgA. Clusters of itchy and burning blisters form on the skin, sometimes in a ring shape, and the mouth can be affected too.

Get an email when new Linear IgA Disease trials open or the FDA decides. Get alerts

Linear IgA Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Linear IgA Disease yet.

Linear IgA Disease has no FDA-approved medicines, 0 open or active clinical trials (0 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

More about Linear IgA Disease

The disease presents with urticarial plaques, vesicles, and flaccid blisters, often in a characteristic annular or clustered pattern known as the "string of pearls" sign. Mucous membranes, most often the mouth and eyes, are involved in many adults, and eye involvement can cause scarring if it is not treated. Unlike bullous pemphigoid, blisters tend to be more vesicular with erosions and crusting rather than large blisters, reflecting the IgA-mediated pathology.

Keep reading about Linear IgA Disease

Diagnosis is definitively confirmed by direct immunofluorescence showing linear IgA deposits at the basement membrane zone without IgG deposition, distinguishing it from bullous pemphigoid. The specific antigen(s) targeted vary among patients; some have antibodies against BP180 (similar to bullous pemphigoid) while others target different antigens such as collagen VII. Clinical severity ranges from mild localized disease to extensive involvement affecting function and quality of life. Prognosis is generally favorable with appropriate treatment, though some patients experience chronic courses with relapses.

What are the symptoms of Linear IgA Disease?

These are common symptoms of Linear IgA Disease, and how strong they are varies from person to person.

  • Clustered blisters in rosette or annular pattern
  • Urticarial and vesicular lesions
  • Pruritus and burning sensation
  • Involvement of face, neck, and flexures
  • Oral mucosal involvement
  • Post-inflammatory hyperpigmentation

Who gets Linear IgA Disease?

Can occur at any age but often affects adults and older individuals, with peak incidence in adults over age 40 and a second peak in children under age 10. Affects males and females equally with no significant gender predominance. More common in Caucasians and individuals of European descent compared to other populations. Has been reported in African, Asian, and Hispanic populations though at lower frequencies.

Drug-induced forms may develop within weeks to months of medication initiation, particularly in middle-aged and older adults taking vancomycin, NSAIDs, or other implicated agents. No significant genetic predisposition pattern identified, though occasional familial clustering reported. Both idiopathic and drug-induced variants affect socioeconomic classes equally.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Linear IgA Disease is diagnosed

Autoimmune blistering disease defined by linear IgA deposits at the basement membrane on direct immunofluorescence; in adults about half of cases are drug-induced, most often by vancomycin. No genetic test has a role.

Trusted Linear IgA Disease resources

Reputable organizations and medical references for learning more about Linear IgA Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Linear IgA Disease

This Linear IgA Disease clinical trial finder lists studies as they become available, with eligibility criteria in plain English. Every trial comes from ClinicalTrials.gov.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

No active clinical trials yet

Linear IgA Disease is a classified rare disease, but clinical trial activity for it is limited. That's part of why we track it. When a trial opens, Trial Friend will have it.

Get an email the moment a Linear IgA Disease trial is registered on ClinicalTrials.gov.

Linear IgA Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Linear IgA Disease patients, caregivers and advocacy groups talk.

Questions people ask about Linear IgA Disease